End-to-end donor screening and manufacturing controls: complementary quality-based strategies to minimize patient risk for donor-derived microbiome therapeutics,Gut Microbes

当前位置： X-MOL 学术 › Gut Microbes › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

End-to-end donor screening and manufacturing controls: complementary quality-based strategies to minimize patient risk for donor-derived microbiome therapeutics
Gut Microbes ( IF 12.2 ) Pub Date : 2024-09-18 , DOI: 10.1080/19490976.2024.2402550
Jason Goldsmith ₁ , Sarah Tomkovich ₁ , John G Auniņš ₁ , Barbara H McGovern ₁ , Jennifer C Mahoney ₁ , Brooke R Hasson ₁ , Christopher W J McChalicher ₁ , David S Ege ₁

Affiliation

Advances in microbiome therapeutics have been motivated by a deeper understanding of the role that the gastrointestinal microbiome plays in human health and disease. The FDA approval of two stool-d...

中文翻译：